Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443378 | 0.88 | KDM4E (0.40) | KDM4EHSD17B10DRD2DRD3ALDH1A1 | |
| SCHEMBL13472656 | 0.85 | DRD2 (0.41) | KDM4EHSD17B10DRD2DRD3ALDH1A1 | |
| SCHEMBL3426497 | 0.85 | OPRM1 (0.36) | KDM4EHSD17B10DRD2DRD3OPRM1 | |
| SCHEMBL172226 | 0.85 | DRD2 (0.46) | KDM4EHSD17B10DRD2DRD3ALDH1A1 | |
| SCHEMBL13662616 | 0.83 | DRD2 (0.40) | KDM4EHSD17B10DRD2DRD3ALDH1A1 | |
| SCHEMBL15746838 | 0.82 | SMN1; SMN2 (0.36) | KDM4EHSD17B10ALDH1A1OPRM1OPRD1 | |
| SCHEMBL11598263 | 0.80 | PLG (0.36) | DRD2DRD3OPRM1OPRD1OPRK1 | |
| SCHEMBL3428866 | 0.80 | KDM4E (0.39) | KDM4EHSD17B10DRD2DRD3ALDH1A1 | |
| SCHEMBL11599522 | 0.79 | OPRM1 (0.31) | OPRM1OPRD1OPRK1 | |
| SCHEMBL21359084 | 0.79 | OPRM1 (0.42) | DRD2DRD3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| EP-1644361-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004113324-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | KDM4E 1084/4885HSD17B10 1752/4885DRD2 4862/4885 |
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | KDM4E 3366/4885HSD17B10 3149/4885DRD2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.